<span item_type="fundamental" item_id="7783e3e402e3351041ca7c3f846c8475" counter_id="ST/US/REVBW" env="prod"></span><span item_type="announcement" item_id="547148018386143745" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -7.01.</p><p></p><h3>Cash and Cash Equivalents</h3><ul><li>As of June 30, 2025, Revelation Biosciences, Inc. had $5.2 million in cash and cash equivalents, a decrease from $6.5 million as of December 31, 2024, primarily due to cash used for operating activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li></ul><h3>Operating Cash Flow</h3><ul><li>Net cash used for operating activities for the three months ended June 30, 2025, was $4.7 million, compared to $5.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>The net loss for the three months ended June 30, 2025, was $2.4 million, or - $7.01 basic and diluted net loss per share, compared to a net loss of $8.4 million, or - $246.27 basic and diluted net loss per share for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li><li>For the six months ended June 30, 2025, the net loss was $4.5 million, or - $13.60 basic and diluted net loss per share, compared to a net loss of $11.1 million, or - $390.02 basic and diluted net loss per share for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Total operating expenses for the three months ended June 30, 2025, were $2.5 million, compared to $2.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li><li>For the six months ended June 30, 2025, total operating expenses were $4.6 million, compared to $4.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Revelation Biosciences, Inc. anticipates announcing data from the Phase 1b study of Gemini later this quarter and plans to engage with the FDA later this year to further the clinical development of Gemini.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm"></span></li></ul>

Revelation Biosciences - CW27 | 8-K: FY2025 Q2 EPS: USD -7.01